Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III neoadjuvant SHR-A1811 monotherapy vs TCbHP in HER2-positive early or locally advanced breast cancer
ChiCTR2600130397Phase 3Completed
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab rezetecan in breast cancer (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall pathologic complete response (tpCR) by IRC. Started Aug 2026; status: completed.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600130397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130397.